These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 31099875

  • 1. Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis.
    Boyne DJ, Cuthbert CA, O'Sullivan DE, Sajobi TT, Hilsden RJ, Friedenreich CM, Cheung WY, Brenner DR.
    JAMA Netw Open; 2019 May 03; 2(5):e194154. PubMed ID: 31099875
    [Abstract] [Full Text] [Related]

  • 2. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D.
    Lancet Oncol; 2014 Dec 03; 15(13):1481-1492. PubMed ID: 25456367
    [Abstract] [Full Text] [Related]

  • 3. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
    Sobrero A, Lonardi S, Rosati G, Di Bartolomeo M, Ronzoni M, Pella N, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Zagonel V, Maiello E, Barni S, Rulli E, Labianca R, TOSCA Investigators.
    J Clin Oncol; 2018 May 20; 36(15):1478-1485. PubMed ID: 29620994
    [Abstract] [Full Text] [Related]

  • 4. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F, Labianca R, Zaniboni A, Lonardi S, Galli F, Rulli E, Rosati G, Corallo S, Ronzoni M, Cardellino GG, Mattioli R, Mambrini A, Ciuffreda L, Banzi M, Pusceddu V, Maiello E, Zampino M, Zagonel V, Marchetti P, Corsi D, Rimassa L, Cinieri S, Sobrero A.
    JAMA Oncol; 2020 Apr 01; 6(4):547-551. PubMed ID: 32053133
    [Abstract] [Full Text] [Related]

  • 5. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
    André T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I, Grothey A, Niedzwiecki D, Saunders M, Labianca R, Yamanaka T, Boukovinas I, Vernerey D, Meyers J, Harkin A, Torri V, Oki E, Georgoulias V, Taieb J, Shields A, Shi Q.
    Lancet Oncol; 2020 Dec 01; 21(12):1620-1629. PubMed ID: 33271092
    [Abstract] [Full Text] [Related]

  • 6. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
    André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J, for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER.
    J Clin Oncol; 2018 May 20; 36(15):1469-1477. PubMed ID: 29620995
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer.
    Loree JM, Sha A, Soleimani M, Kennecke HF, Ho MY, Cheung WY, Mulder KE, Abadi S, Spratlin JL, Gill S.
    Clin Colorectal Cancer; 2018 Jun 20; 17(2):156-163. PubMed ID: 29486916
    [Abstract] [Full Text] [Related]

  • 9. Association of oxaliplatin-containing adjuvant duration with post-treatment fall-related injury and fracture in patients with stage III colon cancer: a population-based retrospective cohort study.
    Sue-Chue-Lam C, Brezden-Masley C, Sutradhar R, Yu AYX, Baxter NN.
    BMC Cancer; 2024 Jul 22; 24(1):878. PubMed ID: 39039514
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
    Souglakos J, Boukovinas I, Kakolyris S, Xynogalos S, Ziras N, Athanasiadis A, Androulakis N, Christopoulou A, Vaslamatzis M, Ardavanis A, Emmanouilides C, Bompolaki I, Kourousis C, Makrantonakis P, Christofyllakis C, Athanasiadis E, Kentepozidis N, Karampeazis A, Katopodi U, Anagnosopoulos A, Papadopoulos G, Prinarakis E, Kalisperi A, Mavroudis D, Georgoulias V.
    Ann Oncol; 2019 Aug 01; 30(8):1304-1310. PubMed ID: 31228203
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer.
    Boyne DJ, Cheung WY, Hilsden RJ, Sajobi TT, Batra A, Friedenreich CM, Brenner DR.
    JAMA Netw Open; 2021 Mar 01; 4(3):e213587. PubMed ID: 33783516
    [Abstract] [Full Text] [Related]

  • 15. Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis.
    Kuang Z, Wang J, Liu K, Wu J, Li J.
    Int J Surg; 2024 May 01; 110(5):3030-3038. PubMed ID: 38349218
    [Abstract] [Full Text] [Related]

  • 16. Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial.
    Yamazaki K, Yamanaka T, Shiozawa M, Manaka D, Kotaka M, Gamoh M, Shiomi A, Makiyama A, Munemoto Y, Rikiyama T, Fukunaga M, Ueki T, Shitara K, Shinkai H, Tanida N, Oki E, Sunami E, Ohtsu A, Maehara Y, Yoshino T.
    Ann Oncol; 2021 Jan 01; 32(1):77-84. PubMed ID: 33121997
    [Abstract] [Full Text] [Related]

  • 17. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A, Yamashita K, Tanioka H, Tsuji A, Inukai M, Yamakawa T, Yamatsuji T, Yoshimitsu M, Toyota K, Yamano T, Nagasaka T, Okajima M.
    Drug Des Devel Ther; 2016 Jan 01; 10():3827-3835. PubMed ID: 27920498
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Optimal duration of adjuvant therapy for stage III colon cancer.
    Kadakia KC, Worrilow WM, Coley H, Salem ME.
    Clin Adv Hematol Oncol; 2019 May 01; 17(5):289-298. PubMed ID: 31188808
    [Abstract] [Full Text] [Related]

  • 20. Changes in Prescribing Patterns in Stage III Colon Cancer.
    Ou FS, Walden DJ, Larson JJ, Kang S, Griswold CR, Ueberroth BE, Patel B, Draper A, Raman P, Alese OB, Sonbol MB, Bekaii-Saab TS, Wu CS, Ahn DH.
    J Natl Compr Canc Netw; 2023 Aug 01; 21(8):841-850.e4. PubMed ID: 37549913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.